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Abstract Serotonin has been implicated in promoting self-
control, regulation of hunger and physiological homeostasis,
and regulation of caloric intake. However, it remains unclear
whether the effects of serotonin on caloric intake reflect purely
homeostatic mechanisms, or whether serotonin also modu-
lates cognitive processes involved in dietary decision making.
We investigated the effects of an acute dose of the serotonin
reuptake inhibitor citalopram on choices between food items
that differed along taste and health attributes, compared with
placebo and the noradrenaline reuptake inhibitor atomoxetine.
Twenty-seven participants attended three sessions and re-
ceived single doses of atomoxetine, citalopram, and placebo
in a double-blind randomised cross-over design. Relative to
placebo, citalopram increased choices of more healthy foods
over less healthy foods. Citalopram also increased the empha-
sis on health considerations in decisions. Atomoxetine did not
affect decision making relative to placebo. The results support
the hypothesis that serotonin may influence food choice by
enhancing a focus on long-term goals. The findings are rele-
vant for understanding decisions about food consumption and
also for treating health conditions such as eating disorders and
obesity.
Keywords Serotonin .Motivation .Action control .Decision
making . Food choice
People often must decide between an option with higher over-
all long-term value and a tempting but ultimately less benefi-
cial option. Optimal decision making in such situations, in-
cluding food choice, requires value computation and action
control (Hare, Camerer, & Rangel, 2009). A growing body of
literature suggests that trade-offs between short-term and
long-term goals are mediated by interactions between the pre-
frontal cortex and subcortical structures (van den Bos et al.,
2013; Dalley, Everitt, & Robbins, 2011), and that the mono-
amine neurotransmitters serotonin (5-HT) and noradrenaline
(NA) may modulate the activity in these systems (Robbins,
2007).
In dietary decision making, there is abundant evidence im-
plicating serotonin in regulation of appetite and caloric intake
(see Carek & Dickerson, 2012; Halford & Harrold, 2011;
Jason et al., 2011). However, it is unclear whether these effects
on caloric intake reflect purely homeostatic mechanisms, or
whether there are also cognitive mechanisms at play. If there
are cognitive mechanisms involved, then this would have po-
tential implications for designing treatments for obesity; for
example, serotonin drugs may be more effective if combined
with cognitive interventions. Furthermore, Doucerain and
Fellows (2012) review the literature on dietary decision mak-
ing and argue that previous research has not used reliable
measures of food intake and choice, which prevents clear un-
derstanding of the underlying cognitive mechanisms. A simi-
lar argument can be made about previous research on the
effect of serotonin on food intake, which has focused mostly
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on studying the quantity of calories consumed rather than on
the psychological and neural mechanisms involved in dietary
decisions. Such deeper understanding would require novel
and theoretically informed experimental designs.
There is evidence that serotonin affects cognitive processes
crucial for action control (Chamberlain et al., 2006; Hyman,
2011) and value-based decision making (Boureau & Dayan,
2011; Seymour et al., 2012). However, the precise role of
serotonin in action control is not well understood (Clark
et al., 2005). Early theoretical accounts suggested that seroto-
nin facilitates behavioural inhibition (Deakin & Graeff, 1991;
Soubrié 1986). More contemporary theories implicate seroto-
nin in inhibiting behaviour in response to aversive predictions
(Boureau & Dayan, 2011; Crockett, Clark, Apergis-Schoute,
Morein-Zamir, & Robbins, 2012; Crockett, Clark, & Robbins,
2009; Dayan & Huys, 2009) and in regulating patience and
impulsivity, thus facilitating long-term optimal behaviours
and suppression of impulsive behaviours (Miyazaki,
Miyazaki, & Doya, 2012; Miyazaki et al., 2014), though these
two accounts have not been fully integrated (Cools,
Nakamura, & Daw, 2011). Recent work in animals (see
Miyazaki et al., 2014) show that the serotonin system en-
hances the ability to wait in order to obtain future reward
and avoid future punishment. Specifically, serotonergic neu-
rons increase their tonic firing rate when rats await rewards
such as food. This evidence implies that serotonin enhances a
focus on longer term goals, although if the same process
operates in humans, this could be any long-term goal.
In this study, we tested the hypothesis that serotonin
promotes a focus on long-term goals in dietary choice. We
manipulated serotonin in healthy volunteers using the
highly selective serotonin reuptake inhibitor (SSRI)
citalopram, which enhances serotonin neurotransmission
by blocking its reuptake and prolonging its actions in
the synapse. To probe the neurochemical specificity of
serotonin in regulating dietary choice, we contrasted the
effects of citalopram with those of atomoxetine, a selec-
tive noradrenaline reuptake inhibitor that boosts noradren-
aline neurotransmission and has a similar side-effect pro-
file as citalopram. There is evidence noradrenaline has a
distinct effect on cognitive flexibility and control
(Chamberlain et al., 2006; Hyman, 2011). This evidence
suggests that noradrenaline promotes inhibitory control in
a global fashion—across different cognitive domains and
executive tasks, which involves sending signals to brain
regions in order to stimulate task-relevant processing and
suppress irrelevant processes (Aron, Dowson, Sahakian,
& Robbins, 2003; Miller & Cohen, 2001; Overtoom
et al., 2003). Therefore, noradrenaline has been implicated
in control of executive function, but not value-based de-
cision making.
In summary, of the distinct varieties of action control, nor-
adrenaline has been implicated in executive control function
(including suppression of unwanted responses), while seroto-
nin has been implicated in the domain of value-based decision
making (includingmodulation of goal values). Here, we tested
the implications of these distinct cognitive mechanisms of
action control for the regulation of dietary choice. This exper-
iment investigated the differential contributions of serotonin
and noradrenaline in dietary choice. Specifically, we exam-
ined choices between healthy and unhealthy foods, in a free-
choice task (i.e. without an explicit goal to eat healthier food),
to investigate how performance is affected by acute manipu-
lations of the serotonergic and noradrenergic systems. If sero-
tonin modulates the weight of long-term goals in value-based
decision making, then increased serotonin transmission will
enhance the focus on health considerations, which will result
in an increased proportion of healthy food choices. In contrast,
if noradrenaline is implicated in control of executive function,
but not value-based decision making, then acute modulation
of noradrenaline will not affect healthy food choice.
Method
Participants
The protocol was approved by the Cambridgeshire Research
Ethics Committee. Thirty healthy subjects (13 males; mean
age, 25.6 years) were screened for neurological and psychiat-
ric disorders by a consultant psychiatrist; each subject gave
written informed consent before participating in the study.
Exclusion criteria were any history of cardiac, hepatic, renal,
pulmonary, neurological, psychiatric or gastrointestinal disor-
ders (including eating disorders), medication/drug use, and
personal or family history of major depression or bipolar af-
fective disorder. Participants were financially compensated
£10 per hour. Two participants dropped out of the study before
completing all three sessions, and a third participant was ex-
cluded from all analyses because of the experience of periph-
eral side effects (dizziness and nausea) that prevented the par-
ticipant from completing the cognitive tasks in at least one
session. The final analysis was carried out in 27 participants
(11 males).
General procedure
Participants attended three sessions at Addenbrooke’s
Hospital in Cambridge, UK (at least 1 week apart) and
received single doses of atomoxetine (60 mg), citalopram
(30 mg), and placebo in a double-blind counterbalanced
design. We selected doses that were clinically relevant
according to established treatment guidelines for atten-
tion-deficit/hyperactivity disorder (atomoxetine) and
obsess ive -compuls ive d i so rde r and depress ion
(citalopram; British National Formulary; www.bnf.org),
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and in line with a previous study in our laboratory
(Chamberlain et al., 2006). At the start of each session,
participants took the drug orally. The food-choice task
was administered as part of a broader testing battery com-
mencing 1.5 hours after capsule administration, and end-
ing approximately 3.5 hours after capsule administration.
The timing of cognitive testing was based on approximate
peak plasma levels for atomoxetine and citalopram (1–
3 hours post capsule administration; Jiang et al., 2013;
Henning & Netter, 2002; Kragh-Sørenson, Overø,
Petersen, Jensen, & Parnas, 1981; Matsui et al., 2012;
Sauer et al., 2005) and prior neurocognitive studies (e.g.
Chamberlain et al., 2006). We attempted to standardize
participants’ baseline hunger levels by instructing them
to eat a regular meal before attending the session and
giving all participants a standard snack (apple) during
the rest period. Participants also completed trait question-
naires during the rest period, including the Restrained
Eating Scale (Herman & Polivy, 1975), which measures
preoccupation with weight and eating behaviour. At the
end of the third session, the participants were debriefed
about whether they had any suspicions about the order of
drug administration; participants did not indicate any in-
sight into the type of drug they received on each session.
Food-choice task
The task had two stages (see also the Appendix). In the
first stage, participants rated the perceived healthiness and
tastiness of foods. In the second stage, participants made
choices between pairs of foods (see Hare et al., 2009, for
a related task). In each testing session, participants were
first presented with 10 food items, in random order, and
asked to rate each item on the dimensions of health and
taste on a visual analogue scale ranging from zero to
1,000 (for better granularity of the measurement, although
the scale can easily be converted to 1–10 range). Table 1
shows the food products used in the choice task in each
session. Five of these items were preselected to be virtues
(higher on health) and the other five were vices (lower on
health). Participants’ ratings across all conditions con-
firmed these distinctions—the average health and taste
ratings across all drug conditions and food types are pre-
sented in Table 2.
Following the ratings, participants were presented with
pairwise combinations of the 10 food items and asked to select
between the two items. Sometimes two virtues were paired,
sometimes two vices were paired, and sometimes a vice was
paired with a virtue. Following each choice, participants were
asked to rate how satisfied they were with their choice. Prior to
the task, participants were informed that upon completion, one
trial would be randomly selected and the participant would
receive the item that they chose on that trial.
To avoid order effects, we used different versions of the
task on each session (see Table 1), each with unique food
items, so that on each session participants made choices with
respect to different food items. Task version was
counterbalanced across participants. Although this exact task
has not been previously published, we note that it is very
similar to another food-choice task that has been widely used
(Hare et al., 2009). The participants’ behaviour (percentage
choice of healthy food) was correlated across sessions—
Sessions 1 & 2: r(27) = .42, p = .029; Sessions 2 & 3: r(27)
= .61, p = .001; Sessions 1 & 3: r(27) = .54, p = .004—and
there was a high interclass correlation coefficient, r = .75,
F(26, 52) = 4.22, p < .001, which suggests good test–retest
reliability.
Results
We focused our analysis on trials where participants made
choices between virtues and vices. Table 3 presents the
Table 1 Food products used in the choice task in each session
Session Virtues Vices
1 Red apple Biscuits
Green grapes Truffles
Strawberry Chelsea bun
Prunes Mill shortbread
Fruit & Nut Donut
2 Green apple Chocolate biscuits
Red grapes Dark chocolate
Cherries Danish
Muesli Pain au chocolat
Mixed nuts Vanilla cupcake
3 Pear Chocolate chip cookie
Blue berries Dairy milk
Apricot Victoria sponge
Raisins Blueberry muffin
Granola bar Chocolate cupcake
Table 2 Average ratings across the drug (citalopram, atomoxetine,
placebo), attribute (liking and healthiness) and food (healthy and
unhealthy) factors
Food Attribute Drug
Placebo Atomoxetine Citalopram
Healthy Liking 373.89 (60.56) 383.10 (46.51) 385.16 (53.84)
Healthiness 451.13 (39.16) 439.37 (43.81) 439.42 (46.04)
Unhealthy Liking 385.93 (73.92) 370.03 (72.98) 377.21 (79.44)
Healthiness 198.07 (43.93) 203.35 (53.54) 192.03 (53.11)
Note. Standard deviations in parentheses
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proportion of healthy choices (i.e., choices for the virtue over
the vice) across the three conditions.
A generalised linear model (generalised estimating equa-
tions) was run with the proportion of healthy choices as the
dependent variable, and Drug condition and Session as
within-subjects factors. The test of model effects revealed that
there was a significant main effect of Drug condition, Wald
chi-square (2) = 7.95, p = .0188; and the parameter estimates
revealed that, relative to placebo, citalopram was a significant
positive predictor of healthy choice, B = .276,Wald (1) = 7.96,
p = .0048. There was neither a significant main effect of
Session, Wald (2) = 1.59, p = .4515, nor an interaction be-
tween Drug and Session, Wald (4) = 5.09, p = .2782; which
shows that our design successfully avoided any order effects.
In a pairwise, Bonferroni-corrected comparison between the
drug conditions, the estimated marginal means for the effect of
Drug revealed that on citalopram participants made a signifi-
cantly higher proportion of healthy choices relative to placebo
(p = .0048), while the proportion of healthy choices did not
significantly differ between atomoxetine and placebo (p =
.1531), or between atomoxetine and citalopram (p = .2575).
We also measured individual differences in eating behav-
iour using the Restrained Eating Scale (Herman & Polivy,
1975). This scale measures preoccupation with weight and
eating behaviour, and participants with scores higher than 17
are classified as restrained eaters. In our sample, the mean
score (+SD) was 9.1 (+3.6). One participant had a score of
18; and the results did not change when excluding this partic-
ipant from the analysis—for example, similarly significant:
main effect of drug condition, Wald chi-square (2) = 6.52, p
= .0384; parameter estimate of the citalopram effect, B = .148,
Wald (1) = 6.30, p = 0.0121; and estimated marginal means
effect of citalopram relative to placebo, p = .0315.
We next investigated how the drugs affected health and
taste ratings of virtues and vices using a repeated-measures
general linear model, with rating as the dependent variable
and Drug (citalopram, atomoxetine, placebo), Attribute (taste
and health), and Food (virtue vs. vice) as within-subjects
factors. The results revealed neither a significant main effect
of Drug, F(2, 52) = 0.21, p = .810, nor an interaction be-
tween Drug and Attribute, F(2, 52) = 0.62, p = .544, or
between Drug and Food, F(2, 52) = 0.28, p = .761, which
suggests that the drugs did not impact participants’ ratings of
the healthiness or tastiness of the food items. Crucially, there
was a significant Food × Attribute interaction, F(1, 26) =
237.68, p < .001, where health ratings were higher for vir-
tues than vices (Mvirtue = 443.31, SD = 42.92; Mvice =
197.81, SD = 49.97), while taste ratings were not different
for vices and virtues (Mvirtue = 380.71, SD = 53.49; Mvice =
377.72, SD = 74.84). There was also a significant effect of
type of Food (virtues, vices), whereby virtue foods were
rated higher than vice food overall across both health and
taste ratings, F(1, 26) = 146.09, p < .001; but this effect
(across all drug conditions) was driven by the difference in
the health attribute rather than the taste attribute. There was
also a main effect of Attribute, F(1, 26) = 63.37, p < .001,
where taste ratings were higher than health ratings overall.
In summary, those results confirm that our selected stimuli
were appropriately distinguished on the basis of their
healthiness.
We assessed the impact of health and taste dimensions
on choice by computing for each attribute the difference
in ratings between the chosen and unchosen options (see
Table 4). The repeated-measures analysis used Drug and
Attribute (health vs. taste) as a within-subject factors, with
the difference in ratings between the chosen and unchosen
options as the dependent variable. There was a significant
main effect of Attribute, F(1, 26) = 6.193, p < .05, where
the chosen–unchosen difference for taste ratings (M =
68.29, SE = 6.83) was greater than the chosen–unchosen
difference for health ratings (M = 24.15, SE = 15.42),
suggesting that, overall, our participants weighted taste
more strongly than health in their choices. However, there
was also a significant interaction between Drug and
Attribute, F(2, 52) = 6.577, p < .01. As Table 4 shows,
there was little variation across the three conditions in
terms of the taste (chosen–unchosen) rating differences,
while the health (chosen–unchosen) ratings showed large
disparities between the conditions. Citalopram showed the
largest difference between ratings in the health dimension.
This pattern implies that on citalopram, participants more
frequently selected the option that had the higher health
Table 3 Proportion of healthy choices across drug conditions
Drug Proportion of healthy choices
Mean SD
Citalopram 0.60 0.30
Atomoxetine 0.54 0.31
Placebo 0.45 0.31
Table 4 Difference between chosen and unchosen foods across
healthiness and liking attributes for each drug condition
Drug Liking difference
(Chosen–Unchosen)
Healthiness difference
(Chosen–Unchosen)
Mean SD Mean SD
Citalopram 66.09 7.11 45.11 17.91
Atomoxetine 67.81 8.71 34.63 17.50
Placebo 70.98 7.97 -7.30 19.54
Cogn Affect Behav Neurosci (2017) 17:542–553 545
rating (i.e., more often the chosen food had a higher
health rating than the rejected food).
One possible alternative explanation for our findings is that
citalopram did not affect decisions bymodulating goal values per
se, but rather made participants less hungry, which in turn made
them less likely to select the vice. To test this, we first examined
whether citalopram and atomoxetine affected hunger ratings.
Baseline hunger levels were moderate across all conditions
(Mcitalopram = 4.59, SD = 1.42; Matomoxetine = 4.82, SD = 1.21;
Mplacebo = 5.46, SD = 0.97). A repeated-measures general linear
model with hunger as the dependent variable and Drug
(citalopram, atomoxetine, placebo) as a within-subject factor re-
vealed a significant main effect of Drug, F(2, 25) = 6.56, p =
.005. Tests of within-subjects linear contrasts revealed that both
citalopram,F(1, 26) = 12.43, p = .002, and atomoxetine,F(1, 26)
= 6.57, p = .017, reduced the ratings of hunger relative to place-
bo. The same pattern was exposed by Bonferroni-corrected
pairwise comparisons between the marginal means for
citalopram and placebo (p = .005), atomoxetine and placebo (p
= .050), but not citalopram and atomoxetine (p = 1.000).
Decreased appetite is a clinically well-known side effect of
atomoxetine (Michelson et al., 2003), but not of citalopram
(Khawam, Laurencic, &Malone, 2006). Furthermore, given that
only citalopram affects choice, we tested whether individual dif-
ferences in the citalopram effect on hunger correlated with the
citalopram effect on choice (i.e. those subjects who showed
stronger citalopram effects on hunger also showed the stronger
citalopram effects on choice). This correlation was indeed nega-
tive and significant, r(27) = -.42, p = .029, which warranted a
mediation analysis (Judd, Kenny, & McClelland, 2001) to test
whether changes in hunger caused by citaloprammediated drug-
induced changes in self-control. In the mediation analysis, the
direct effect of citalopram on choice was again significant, t(26)
= 2.51, p = .0186. The indirect (mediation) effect of citalopram
on choice through hunger was only marginally significant (Z =
1.75, p = .081). Therefore, citalopram’s effects on food choice
could partially be attributed to changes in appetite.
Finally, citalopram-induced changes in dietary choice could
be caused by nonspecific side effects, such as nausea, of
citalopram (Khawam et al., 2006). In our study, we also asked
the participants to rate their experience of eight ‘mood’ states in
every condition. We ran a multivariate ANOVA (GLM) with
Mood ratings as the dependent variable and Drug as the within-
subjects measure. All mood ratings were insignificant, apart
from Bnauseous^: positive affect: F(2,81) = 1.572, p > .05;
negative affect: F(2, 81) = 1.290, p > .05; drowsy: F(2, 81) =
.570, p > .05; hostile: F(2, 81) = .390, p > .05; irritable: F(2, 81)
= .195, p > .05; energetic: F(2, 81) = .593, p > .05; attentive:
F(2, 81) = .967, p > .05; nauseous: F(2, 81) = 6.079, p = .003.
Planned comparisons showed that nausea was higher in the
atomoxetine (M = 65.61, SD = 98.34) than in the citalopram
(M = 31.46, SD = 86.74) and the placebo (M = -11.11, SD =
87.39) groups, respectively. We ran a mediation analysis of the
citalopram versus placebo effect on choice, with nausea as the
mediator, but the mediation effect was not significant (Z = 0.99,
p = .324), while the total effect of citalopram on choice was
significant, t(26) = 2.51, p = .0186.
Discussion
We found that acute citalopram increased choices for healthy
foods relative to placebo, and this appeared to be driven by a
greater emphasis on the health, rather than taste, attributes of food
items. In contrast, atomoxetine did not appear to significantly
affect the proportion of healthy choices relative to placebo.
Citalopram did not significantly impact food choice relative to
atomoxetine, however. Thus, our data tentatively suggest that
serotonin amplifies the importance of health considerations in
consumption decisions, perhaps via enhancing a focus on, or
the value of, long-term outcomes. The lack of a direct effect of
the drug on health or taste ratings of food items also suggests
serotonin promotes integration of health information into choices
rather than influencing the health ratings themselves. This result
also supports the standard hypothesis that serotonin can facilitate
behavioural inhibition (Boureau & Dayan, 2011; Deakin &
Graeff, 1991; Soubrié, 1986), as a result of impacting the
weighting of health outcomes or goals in value-based choice.
The effect of citalopram was only partially mediated by a
reduction of appetite (i.e. the participants were more likely to
select virtue foods, and reject vice foods, when they were less
hungry). This marginal mediation implies that serotonin may
impact cognitive processes (i.e. a focus on health), appetite, as
well as the interaction between appetite and cognition (i.e. a
reduced appetite may focus one’s attention on the value of
health and long-term goals in general). The finding that
atomoxetine also reduces hunger, but does not significantly
affect choice, supports the interpretation that citalopram may
have an independent effect on cognitive processes.
There is an extensive literature on food choice following
serotonin releasing drugs such as fenfluramine (Wurtman &
Wurtman, 1979; Wurtman et al., 1985). Specifically,
Wurtman’s early data and theories reveal how serotonin shifts
food choice from carbohydrate to protein—serotoninergic
drugs depress food intake and carbohydrate consumption
without impacting protein consumption. Other researchers
have tended to focus on more dietary aspects of the effects
of serotonergic regulation (see Blundell, 1992). This research
reveals that serotonin in the body mediates nutritional input
and the feeding drive. Specifically, manipulation of serotonin
causes changes in feeding behaviour, such as when serotoner-
gic activation leads to selective avoidance of fat in the diet
(Blundell, Lawton, & Halford, 1995); whereas serotonergic
activation is modulated by nutritional variables such as the
proportion of carbohydrate, the availability of specific macro-
nutrient sources, the degree of hydration, and the circadian
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preference for specific nutrients (Blundell, 1992). This litera-
ture on food choice could, in principle, explain some of the
observed effects on choice in our study—specifically, the re-
duced preference for vices, because those foods predominant-
ly contain carbohydrate and fat (see Table 1). However, this
literature cannot account for the observation that the
citalopram’s effect is driven by a greater emphasis on the
health rather than taste attribute in choice, specifically the
effect on the frequency of selecting the option that has higher
health rating. Therefore, we conclude that serotonin can im-
pact dietary decisions by enhancing the impact of health in-
formation and long-term goals.
In terms of a mechanistic interpretation of our findings, we
speculate that serotonin modulates the functional connectivity
between ventromedial prefrontal cortex (vmPFC) and dorsolat-
eral prefrontal cortex (DLPFC). This interpretation is motivated
by evidence that preference for healthier food items in similar
dietary decision tasks is linked to increased functional connectiv-
ity between vmPFC andDLPFC regions encoding foods’ health-
iness (Hare et al., 2009; Maier, Makwana, & Hare, 2015). Note
that although those studies were not concerned with the role of
serotonin, they nevertheless employed a very similar dietary de-
cision task. Therefore, such connectivity changes could also pro-
vide a plausible mechanism for integrating health information
into food choice under the increased influence of serotonin.
This interpretation is consistent with Miyazaki et al.’s (2012)
hypothesis that serotonin enhances prefrontal regulation of ac-
tion, most likely through structures such as the medial prefrontal
and orbitofrontal cortices, which are involved in value-based
decision making. The current data demonstrate that this effect
of serotonin occurs not only during the regulation of behaviour
whilst waiting for (food) reward (Miyazaki et al., 2014) but also
during other self-control problems such as (food) choice. In sum-
mary, our resultsmay shed light on the underlying neurochemical
substrates involved in self-control.
We acknowledge the small sample size as a key limitation
of this study, given the observed effects are relatively weak,
which invites the need for future replications with larger sam-
ples and more heterogeneous populations (healthy partici-
pants as well as individuals undergoing weight-loss
treatment).
The findings also have implications for understanding and
treating health conditions such as eating disorders and obesity.
For example, serotonin enhancing drugs could be given dur-
ing initial stages of behaviour change interventions aiming to
change the lifestyle of overweight individuals and obese pa-
tients. Similarly, the affected cognitive processes also have
important implications for disorders of human decision mak-
ing such as addiction and impulsive behaviours.
Pharmacological treatments that enhance the weight of long-
term goals in value-based decision making might support psy-
chological therapies for such mental health conditions.
Finally, targeting the serotonin system and its impact on value
computation in decision making offers the potential for better
understanding consumer food preferences and behaviour.
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Appendix
Methodological details
The task was run in E-Prime software (Schneider, Eschman, &
Zuccolotto, 2012).
Participants saw the following instructions:
BYou will now see a series of items. Please assign a rating
to each item by clicking the mouse once on the provided
scale. If you can’t tell what an item is, please notify the
experimenter.^
BYou will now see pairs of items. Please select which
item you would like to eat at the end of the experiment.
Click the left mouse button to select the item on the left,
or click the right mouse button to select the item on the
right.^
BAfter you have made your decision, you will be asked to
rate how satisfied you feel with your decision.^
BOne of these trials will be selected by the computer at the
end of the task and you will receive the item you chose in
that trial, so treat each choice as if it were the only one.^
Participants saw the following stimuli:
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